The Endocannabinoid Activity Remodulation for psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis
Preprint in Research Square (March 2024)